These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 2906221

  • 1. Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
    Subbotina TI, Tenkova TV, Sidorova LV, Shpilyuk GF, Drinevsky VP, Voitsekhovskaya EM, Konstantinov VK, Sominina AA.
    Acta Virol; 1988 Nov; 32(6):494-502. PubMed ID: 2906221
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Nov; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 3. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.
    Avtushenko SS, Sorokin EM, Zoschenkova NY, Zacharova NG, Naichin AN.
    J Biotechnol; 1996 Jan 26; 44(1-3):21-8. PubMed ID: 8717382
    [Abstract] [Full Text] [Related]

  • 4. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S, Süss J, Oehring H, Schmidt J.
    Acta Virol; 1982 Dec 26; 26(6):466-73. PubMed ID: 6132540
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 26; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 6. Characteristic of humoral response of elderly to inactivated influenza vaccine.
    Siennicka J.
    Arch Immunol Ther Exp (Warsz); 1996 Sep 26; 44(5-6):389-94. PubMed ID: 9017157
    [Abstract] [Full Text] [Related]

  • 7. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730
    [Abstract] [Full Text] [Related]

  • 8. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 17; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM.
    Vaccine; 2005 Jul 08; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [Abstract] [Full Text] [Related]

  • 10. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 11. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D.
    J Rheumatol; 2002 Dec 27; 29(12):2555-7. PubMed ID: 12465151
    [Abstract] [Full Text] [Related]

  • 12. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].
    Lupulescu E, Ioniţă E, Botez D, Matepciuc M, Tabra ME, Tecu C, Alexandrescu V, Munţiu A.
    Bacteriol Virusol Parazitol Epidemiol; 1997 Dec 27; 42(1-2):110-2. PubMed ID: 9235136
    [No Abstract] [Full Text] [Related]

  • 13. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Ogra PL.
    J Immunol; 1987 May 01; 138(9):3010-3. PubMed ID: 3571981
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 15. Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic.
    Stumpa A, Cihla F, Tůmová B, Husek V, Slezácek J.
    Acta Virol; 1979 Sep 15; 23(5):443-5. PubMed ID: 42307
    [Abstract] [Full Text] [Related]

  • 16. [The evaluation of the reactogenicity and immunological activity of an inactivated 3-component influenza vaccine with an elevated hemagglutinin concentration in the inoculation dosage].
    Marinich IG, Shadrin AS, Naĭkhin AN, Ivannikov IuG, Kuznetsov NP, Karogodina VI, Shcherbinskaia AM, Voronina EG, Stepankovskaia LD, Eliseeva IV.
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul 15; (7):58-61. PubMed ID: 1950267
    [Abstract] [Full Text] [Related]

  • 17. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2004 Jun 30; 22(20):2566-77. PubMed ID: 15193382
    [Abstract] [Full Text] [Related]

  • 18. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 19. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.
    J Med Virol; 2001 Sep 25; 65(1):178-84. PubMed ID: 11505461
    [Abstract] [Full Text] [Related]

  • 20. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.